🧬 This trial will evaluate ProtheraCytes®, a therapy aimed at improving survival after heart attacks.
📅 Tech transfer occurs this year, with clinical batch production expected in 2026.
🚀 CellProthera’s CEO highlights the partnership’s value as they approach market authorization.
Introduction:
CellProthera, a company based in France, has selected CELLforCURE by SEQENS as its contract development and manufacturing organization (CDMO) for a forthcoming Phase III clinical trial involving its innovative stem cell therapy, ProtheraCytes®. This therapy aims to enhance survival rates in patients experiencing heart failure following a severe myocardial infarction.
- CellProthera has chosen CELLforCURE by SEQENS for GMP manufacturing in its upcoming Phase III trial.
- The trial targets ProtheraCytes®, which are autologous expanded CD34+ stem cells intended to improve heart failure prognosis.
- The company plans to initiate the tech transfer to CELLforCURE in 2025, with clinical batch production anticipated to begin in 2026.
- CellProthera received favorable advice from the FDA regarding its Phase III trial design, marking a significant milestone in its development journey.
- The collaboration leverages CELLforCURE’s proven expertise in producing commercial batches of autologous therapies, which is vital for successful trial progression.
Conclusion:
This partnership underscores the importance of selecting a capable manufacturing partner in the development of advanced therapies. As CellProthera approaches pivotal stages of its clinical trial, the collaboration with CELLforCURE is positioned to expedite the path toward market authorization, potentially offering new hope for individuals affected by heart failure.
